Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TURANDOT pre-operative nivolumab in PD-L1-positive resectable urothelial cancer
NL-OMON52369Phase 1Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab in transitional cell carcinoma (TCC), sponsored by Netherlands Cancer Institute. Primary endpoint: Feasibility. Started Sep 2021; status: completed.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON52369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52369.